HanchorBio Turns Clinical Progress into Global Pharma Partnering Momentum at BIO-Europe 2026
Meetings secured with 86% of top-priority multinational pharma targets as expanding clinical evidence and precision partnering open new opportunities across oncology, autoimmune diseases, and global markets.
TAIPEI, SAN FRANCISCO, and SHANGHAI — November 19, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced strong global business development momentum following BIO-Europe 2026 in Cologne, Germany.
The conversation around HanchorBio’s science is shifting—and so are global partnering opportunities.
During broad industry outreach in the first half of 2025, HanchorBio engaged 153 companies. Nearly half remained open to future discussions, while prospective partners emphasized the need for stronger human clinical evidence before advancing conversations on CD47/SIRPα-directed therapies.
At BIO-Europe 2026, supported by HCB101’s growing clinical dataset and a precision partnering strategy, HanchorBio secured meetings with 86% of its AI-prioritized top-tier multinational pharmaceutical targets. Leveraging AI-informed partner intelligence and tailored scientific presentations, the Company advanced discussions beyond introductory briefings to concrete evaluations of HCB101 across partners’ oncology portfolios and of HCB206’s potential in autoimmune diseases. These substantive dialogues identified actionable pathways toward joint scientific evaluations, co-development, and strategic licensing.
“A year ago, our outreach focused primarily on introducing our science and building awareness. Today, our expanding clinical evidence is driving a fundamentally different level of engagement with global pharmaceutical leaders,” said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. “We are now exploring specific ways HCB101 can complement established oncology portfolios, while HCB206 opens an entirely new frontier in autoimmune diseases. Our focus is turning these scientific connections into meaningful development partnerships that accelerate innovation and create long-term global value.”
HCB101: One Clinical Anchor. Multiple Combination Opportunities.
HCB101’s emerging clinical data continues to strengthen its scientific rationale as a versatile combination backbone across diverse oncology modalities. At BIO-Europe 2026, discussions with multinational pharmaceutical companies explored how HCB101’s macrophage-directed mechanism could complement:
- EGFR-targeted antibodiesin colorectal and head and neck cancers
- PD-L1/VEGF bispecificsintegrating immune checkpoint and tumor microenvironment modulation
- Antibody-drug conjugates (ADCs)pairing targeted tumor-cell killing with macrophage-mediated clearance
- Therapeutic cancer vaccineslinking immune priming with innate antitumor immunity.
Parallel discussions with emerging biotechnology innovators explored engineered immunotherapies and other novel mechanisms to further broaden HCB101’s potential. Each combination strategy will require further scientific evaluation, safety assessment, and clinical development planning.
HCB206: Expanding Beyond Oncology
HCB206, HanchorBio’s investigational CD20 × SIRPα bispecific fusion protein, is attracting strong interest for its potential to differentiate in B-cell-mediated autoimmune diseases. Discussions with multinational pharmaceutical and autoimmune-focused biotechnology companies are exploring the opportunity for this dual-mechanism approach—combining CD20-directed B-cell targeting with macrophage checkpoint modulation—to achieve deeper, broader tissue clearance and potentially more durable B-cell depletion than current standards of care.
With systemic lupus erythematosus (SLE) as its lead planned autoimmune indication, HCB206 represents a second major therapeutic and partnership pillar for the Company. Partner dialogues covered comparative biology, pharmacokinetics, dosing, and clinical development strategies. HCB206’s current data support near-term IND filings, with solid safety and excellent efficacy profiles in preclinical studies.
Multiple Paths to Global Value Creation
BIO-Europe 2026 underscored the breadth of HanchorBio’s global partnering strategy—spanning HCB101 as an oncology combination backbone, HCB206 as a differentiated autoimmune asset, and regional licensing opportunities in high-growth markets such as the Middle East and North Africa (MENA) to expand global reach.
Powered by the versatility of its proprietary FBDB™ platform, HanchorBio is well-positioned to pursue multiple development and commercialization pathways. As the science opens doors and precision partnering brings key decision-makers to the table, the Company’s next priority is to convert this momentum into formal collaborations that accelerate clinical development, expand global reach, and deliver lasting value for patients and shareholders.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company dedicated to Reimagining Immunotherapy for Patients Worldwide. Through its proprietary FBDB™ platform, HanchorBio develops next-generation biologics that integrate innate and adaptive immune mechanisms across oncology and immune-mediated diseases. Its pipeline includes HCB101, a clinical-stage SIRPα-based macrophage checkpoint program; HCB206, an investigational CD20 × SIRPα bispecific fusion protein; and additional next-generation multispecific biologics.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s investigational products, clinical development, combination strategies, business development activities, potential partnerships, licensing opportunities, and commercialization plans. These statements are subject to scientific, clinical, regulatory, and commercial risks and uncertainties. Preliminary findings may not predict future results, and discussions with prospective partners do not guarantee future collaborations, licensing agreements, or transactions. Actual results may differ materially from expectations. Except as required by applicable law, HanchorBio undertakes no obligation to update these statements.
HanchorBio Business Development Contact:
Email: [email protected]
Investor & Media Contact:
Email: [email protected]
漢康生技於 BIO-Europe 2026 展現臨床研發成果 推動全球藥廠策略合作新契機
以持續累積的臨床數據及精準商務合作策略,成功與 86% 優先鎖定的全球大型藥廠洽談,拓展腫瘤、自體免疫疾病及全球市場合作機會
【台北、上海、舊金山,2026 年 11 月 19 日】-全球臨床階段生技公司漢康生技(TWSE:7827)今日宣布,公司於德國科隆舉行的 BIO-Europe 2026 國際生技合作大會中,在全球商務開發方面取得積極進展,展現持續累積的臨床研發成果正逐步轉化為國際策略合作機會。
隨著漢康生技臨床研發成果持續推進,全球藥廠對公司創新技術的關注及合作討論,也正進入新的階段。
2025 年上半年,漢康生技廣泛接洽全球 153 家企業,其中近半數表示願意持續保持交流。然而,潛在合作夥伴當時普遍認為,針對 CD47/SIRPα 作用機制的治療策略,仍需要更多人體臨床數據支持,才能進一步推動實質合作討論。
在本屆 BIO-Europe 2026 大會中,憑藉 HCB101 持續累積的臨床數據,以及精準商務合作策略,漢康生技成功與透過人工智慧(AI)分析優先鎖定的全球大型跨國藥廠中,86% 的優先合作對象安排洽談。公司運用 AI 輔助合作夥伴分析及客製化科學簡報,將合作討論從初步技術介紹,進一步推進至評估 HCB101 與各藥廠現有腫瘤產品組合的互補潛力,以及 HCB206 在自體免疫疾病領域的應用機會。相關實質交流亦為後續共同科學評估、合作開發及策略授權開啟具體合作方向。
漢康生技創辦人、董事長暨執行長劉世高博士表示:「一年前,我們的商務開發工作主要著重於介紹公司的創新技術,並提升國際市場對漢康的認識。如今,隨著臨床數據持續累積,全球大型藥廠與我們的合作討論已進入截然不同的階段。我們正積極探索 HCB101 如何與現有腫瘤治療產品組合形成互補,同時 HCB206 也為公司開拓自體免疫疾病領域的全新發展機會。我們的目標是將這些科學交流轉化為具實質意義的研發合作,加速創新技術發展,並創造長期的全球價值。」
HCB101:以臨床數據為基礎,拓展多元腫瘤聯合治療機會
HCB101 持續累積的早期臨床數據,進一步支持其作為多元腫瘤治療模式中聯合治療基礎藥物的科學依據。
在 BIO-Europe 2026 大會期間,漢康生技與多家跨國藥廠深入探討 HCB101 以巨噬細胞為導向的作用機制,如何與不同腫瘤治療策略形成互補,包括:
- EGFR 標靶抗體: 探索於結直腸癌及頭頸癌治療中的聯合應用機會。
- PD-L1/VEGF 雙特異性抗體: 結合免疫檢查點調控與腫瘤微環境調節機制。
- 抗體藥物複合體(ADC): 結合標靶性腫瘤細胞殺傷作用與巨噬細胞介導的清除機制。
- 治療性癌症疫苗: 串聯免疫系統啟動與先天性抗腫瘤免疫反應。
此外,漢康生技亦與新興生技創新企業展開平行交流,探討工程化免疫療法及其他新型作用機制,以進一步拓展 HCB101 的潛在應用範圍。各項聯合治療策略仍須經過進一步科學評估、安全性評估及臨床開發規劃。
HCB206:拓展腫瘤以外的自體免疫疾病治療領域
HCB206 為漢康生技研發中的 CD20 × SIRPα 雙特異性融合蛋白,因其在 B 細胞介導的自體免疫疾病中具備潛在差異化優勢,受到國際藥廠高度關注。
漢康生技與跨國藥廠及專注於自體免疫疾病領域的生技公司展開討論,探索 HCB206 結合 CD20 標靶 B 細胞作用與巨噬細胞免疫檢查點調控的雙重作用機制,是否有機會相較於現行標準治療,實現更深入、更廣泛的組織內 B 細胞清除效果,並可能帶來更持久的 B 細胞耗竭作用。
HCB206 以全身性紅斑性狼瘡(SLE)作為首要規劃開發的自體免疫疾病適應症,為漢康生技建立繼腫瘤治療領域之外的第二大治療及策略合作發展主軸。
此次合作討論涵蓋比較生物學、藥物動力學、給藥劑量及臨床開發策略等面向。HCB206 目前的研究數據支持公司於近期推進新藥臨床試驗申請(IND),且其臨床前研究已展現良好的安全性及優異的療效表現。
多元全球合作策略 創造長期發展價值
BIO-Europe 2026 進一步展現漢康生技全球策略合作布局的多元性,涵蓋以 HCB101 作為腫瘤聯合治療的基礎藥物、以 HCB206 作為具差異化潛力的自體免疫疾病候選藥物,以及拓展中東與北非(MENA)等高成長市場的區域授權合作機會,持續擴大全球市場布局。
憑藉自主開發的 FBDB™ 多功能生物藥平台所具備的技術靈活性,漢康生技得以探索多元研發及商業化發展途徑。隨著創新科學成果持續開啟國際合作機會,精準商務合作策略亦促進公司與全球藥廠關鍵決策者展開實質交流。
漢康生技下一階段將致力於把握目前的合作進展,推動正式合作關係的建立,以加速臨床開發、拓展全球市場,並為病人及股東創造長期價值。
關於漢康生技
漢康生技(TWSE:7827)是一家全球臨床階段生技公司,致力於「重新定義免疫療法,造福全球病患」(Reimagining Immunotherapy for Patients Worldwide)。透過自主開發的 FBDB™ 多功能生物藥平台,漢康生技致力於開發整合先天性與後天性免疫機制的下一代創新生物藥,涵蓋腫瘤及免疫介導疾病領域。
公司產品管線包括處於臨床開發階段、以 SIRPα 為基礎的巨噬細胞免疫檢查點候選藥物 HCB101、研發中的 CD20 × SIRPα 雙特異性融合蛋白 HCB206,以及其他下一代多特異性生物藥。
更多資訊請參閱:www.HanchorBio.com。
前瞻性聲明
本新聞稿包含有關漢康生技研發中產品、臨床開發、聯合治療策略、商務開發活動、潛在合作關係、授權機會及商業化計畫之前瞻性聲明。此類聲明涉及科學、臨床、法規及商業方面的風險與不確定性。初步研究結果未必能預測未來成果,與潛在合作夥伴進行討論亦不保證未來必然達成合作、授權協議或相關交易。實際結果可能與預期存在重大差異。除適用法律另有規定外,漢康生技不承擔更新此類聲明之義務。

